Therapeutic effect and clinical evaluation of Eltrombopag (Revlan)

Eltrombopag is an oral thrombopoietin receptor agonist (TPO-RA). It mainly simulates the action of thrombopoietin (TPO), activates bone marrow megakaryocyte receptors and promotes platelet production, thereby effectively improving platelet levels in patients with thrombocytopenia. Clinical studies have shown that eltrombopag has shown good efficacy in a variety of thrombocytopenic diseases such as chronic immune thrombocytopenic purpura (ITP), chronic liver disease-related thrombocytopenia, and aplastic anemia. Its oral administration method has obvious advantages compared with traditional blood transfusion treatment, improving patients' compliance and life convenience.

In patients with chronic ITP, eltrombopag can significantly increase platelet count and reduce the incidence of bleeding events. Multiple clinical trials have shown that most patients' platelet levels can be maintained above 50×10^9/L after using eltrombopag, and the risk of bleeding is significantly reduced. This effect not only improves the patient's clinical symptoms but also reduces dependence on hormones or immunosuppressants, thereby reducing the risk of long-term side effects. Long-term use in some patients can maintain stable platelet levels and achieve sustained effects in disease management.

In patients with thrombocytopenia associated with chronic liver disease, short-term use of eltrombopag before surgery or invasive procedures has also shown good efficacy. Studies have shown that taking eltrombopag can significantly increase platelet counts within days, reducing the risk of bleeding during surgery or endoscopic procedures, thereby avoiding or reducing the need for blood transfusions. This rapid onset of action makes eltrombopag an important clinical choice for the safe management of patients with platelet shortages.
From the overall clinical evaluation, eltrombopag has shown good effects in increasing platelet count, reducing bleeding events and improving patients' quality of life. Its safety is generally controllable. Common adverse reactions include headache, fatigue and mild liver function abnormalities, most of which are mild to moderate and reversible. Through individualized dose adjustment and regular monitoring of blood and liver function, the vast majority of patients can use eltrombopag safely and long-term to achieve effective management of platelet levels and disease control.
Reference: https://www.drugs.com/